Information  X 
Enter a valid email address

CIP Merchant Capital (CIP)


Monday 12 April, 2021

CIP Merchant Capital

Investment in Ixico plc

RNS Number : 0690V
CIP Merchant Capital Ltd
12 April 2021

12 April 2021



("CIP" or the "Company")


Investment in Ixico plc


CIP is pleased to announce its investment in Ixico plc (AIM: IXI) ("Ixico"), the artificial intelligence data analytics company delivering insights in neuroscience, quoted on AIM. The Company has acquired, in aggregate, 1,784,500 ordinary shares of 1p each in Ixico, representing approximately 3.72 per cent. of Ixico's issued share capital, for a total consideration of approximately £1.2 million.


For its financial year ended 30 September 2020, Ixico achieved revenue of £9.53 million, gross profit of £6.35 million,  a profit on ordinary activities before taxation of £0.86 million and a net profit attributable to its equity holders of £0.95 million. As at 30 September 2020, Ixico had cash and cash equivalents of £7.95 million and net assets of £9.12 million. Currently, Ixico has a market capitalisation of approximately £33.82 million.


The CIP Board notes the contract update released by Ixico on 23 March 2021 in respect of the Huntingdon's disease phase III trial and open-label extension studies by its largest pharma customer and the subsequent adverse movement in its share price. The Company's Board believes that, regardless of such update's potential short term impact on Ixico's financial performance, Ixico nevertheless maintains a solid pipeline with a contracted order book underpinned by its advanced data analytics capability in neuroscience.



For further information, please contact :


Merchant Capital Manager Limited (Investment Manager)

Wikus Van Schalkwyk


+ 44 1481 749363

Strand Hanson Limited (Nominated Adviser and Broker)

James Bellman / Matthew Chandler / Ritchie Balmer

+44 20 7409 3494



The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European (Withdrawal) Act 2018.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t